Landmark trial
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Brand DH, Tree AC, Ostler P, et al.
DoseLab summary
Randomized phase 3 trial of SBRT versus conventionally or moderately hypofractionated IMRT for localized prostate cancer; acute toxicity report. Later reports give 2-year toxicity and 5-year outcomes.
Why this is useful
The phase 3 trial behind five-fraction prostate SBRT; source of most bladder, rectum, small bowel and penile bulb values in the SBRT table.
Reference details
- Title
- Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
- Authors / organization
- Brand DH, Tree AC, Ostler P, et al.
- Publication / protocol
- Lancet Oncol. 2019;20(11):1531–1543
- Version
- Pending verification
- Year
- 2019
- DOI
- Pending verification
- Disease sites
- Prostate
- Topics
- Prostate, SBRT, Landmark trial
- Fractionation context
- SBRT (5 fractions) vs conventional or moderate hypofractionation
- Last reviewed by DoseLab
- Pending verification